1 Lacolley P, Regnault V, Nicoletti A, et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res, 2012, 95: 194-204
[2]
2 Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones, 2007, 39: 86-93
[3]
3 Hao H, Gabbiani G, Bochaton-Piallat M L. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscl Throm Vasc Biol, 2003, 23: 1510-1520
[4]
4 Shi N, Chen S Y. Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res, 2014, 28: 40-46
[5]
5 Hu J, Van den Steen P E, Sang Q X, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov, 2007, 6: 480-498
[6]
6 Newby A C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res, 2006, 69: 614-624
[7]
7 Sluijter J P, de Kleijn D P, Pasterkamp G. Vascular remodeling and protease inhibition—bench to bedside. Cardiovasc Res, 2006, 69: 595-603
[8]
8 Dwivedi A, Slater S C, George S J. MMP-9 and -12 cause N-cadherin shedding and thereby β-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res, 2009, 81: 178-186
[9]
9 Liu C J, Kong W, Ilalov K, et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J, 2006, 20: 988-990
[10]
10 Wang L, Zheng J, Bai X, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res, 2009, 104: 688-698
[11]
11 Wang L, Zheng J, Du Y, et al. Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with a7b1 integrin. Circ Res, 106: 514-525
[12]
12 Du Y, Gao C, Liu Z, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscl Throm Vasc Biol, 2012, 32: 2580-2588
[13]
13 Du Y, Wang Y, Wang L, et al. Cartilage oligomeric matrix protein inhibits vascular smooth muscle calcification by interacting with bone morphogenetic protein-2 novelty and significance. Circ Res, 2011, 108: 917-928
[14]
14 Schunkert H, Konig I R, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet, 2011, 43: 333-338
[15]
15 Reilly M P, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet, 2011, 377: 383-392
[16]
16 Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet, 2011, 43: 339-344
[17]
17 Pu X, Xiao Q, Kiechl S, et al. ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary- artery-disease-associated variant. Am J Hum Genet, 2013, 92: 366-374
[18]
18 Apte S S. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem, 2009, 284: 31493-31497
[19]
19 Luque A, Carpizo D R, Iruela-Arispe M L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem, 2003, 278: 23656-23665
[20]
20 Rocks N, Paulissen G, Quesada-Calvo F, et al. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res, 2008, 68: 9541-9550
[21]
21 Stanton H, Rogerson F M, East C J, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature, 2005, 434: 648-652
[22]
22 Glasson S S, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature, 2005, 434: 644-648
[23]
23 Tortorella M D, Burn T C, Pratta M A, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science, 1999, 284: 1664-1666
[24]
24 Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 1998, 91: 2839-2846
[25]
25 Salter R C, Ashlin T G, Kwan A P, et al. ADAMTS proteases: key roles in atherosclerosis? J Mol Med (Berl), 2010, 88: 1203-1211
[26]
26 Jonsson-Rylander A C, Nilsson T, Fritsche-Danielson R, et al. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscl Throm Vasc Biol, 2005, 25: 180-185
[27]
27 Sabatine M S, Ploughman L, Simonsen K L, et al. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscl Throm Vasc Biol, 2008, 28: 562-567
[28]
28 Wagsater D, Bjork H, Zhu C, et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis, 2008, 196: 514-522
[29]
29 Didangelos A, Mayr U, Monaco C, et al. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem, 2012, 287: 19341-19345
[30]
30 Lindner V, Reidy M A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA, 1991, 88: 3739-3743
[31]
31 Ferns G A, Raines E W, Sprugel K H, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science, 1991, 253: 1129-1132
[32]
32 Tsai S, Hollenbeck S T, Ryer E J, et al. TGF-b through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol, 2009, 297: H540-H 549
[33]
33 Min L J, Mogi M, Li J M, et al. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res, 2005, 97: 434-442
[34]
34 Grant M B, Wargovich T J, Ellis E A, et al. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation, 1994, 89: 1511-1517
[35]
35 Elledge S J. Cell cycle checkpoints: preventing an identity crisis. Science, 1996, 274: 1664-1672
[36]
36 Koepp D M, Harper J W, Elledge S J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell, 1999, 97: 431-434
[37]
37 Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene, 2000, 247: 1-15
[38]
38 Bendeck M P, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol, 2002, 160: 1089-1095
[39]
39 Islam M M, Franco C D, Courtman D W, et al. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am J Pathol, 2003, 163: 1557-1566
[40]
40 Cho A, Reidy M A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res, 2002, 91: 845-851
[41]
41 Galis Z S, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res, 2002, 91: 852-859
